Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
P 1 (3)

Trial Status

Completed1
Active Not Recruiting1
Withdrawn1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT03435952Phase 1Active Not Recruiting

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

NCT03114462Phase 1RecruitingPrimary

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

NCT03523689CompletedPrimary

Radial-Probe Endobronchial Ultrasound in Detecting Atelectasis in Patients Undergoing Peripheral Bronchoscopy

NCT02915172Phase 1Withdrawn

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Showing all 4 trials

Research Network

Activity Timeline